EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Enhancing pharmacogenomic data accessibility and drug safety with large language models: a case study with Llama3.1

Dan Li, Leihong Wu, Ying-Chi Lin, Ho-Yin Huang, Ebony Cotton, Qi Liu, Ru Chen, Ruihao Huang, Yifan Zhang, Joshua Xu

Experimental Biology and Medicine · 2024

DOI: 10.3389/ebm.2024.10393 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimental Biology and Medicine, 2024. Verfasst von Dan Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, United St…. Hauptthemen laut MEDLINE: Pharmacogenetics. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmacogenomics (PGx) holds the promise of personalizing medical treatments based on individual genetic profiles, thereby enhancing drug efficacy and safety. However, the current landscape of PGx research is hindered by fragmented data sources, time-consuming manual data extraction processes, and the need for comprehensive and up-to-date information. This study aims to address these challenges by evaluating the ability of Large Language Models (LLMs), specifically Llama3.1-70B, to automate and improve the accuracy of PGx information extraction from the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling (FDA PGx Biomarker table), which is well-structured with drug names, biomarkers, therapeutic area, and related labeling texts. Our primary goal was to test the feasibility of LLMs in streamlining PGx data extraction, as an alternative to traditional, labor-intensive approaches. Llama3.1-70B achieved 91.4% accuracy in identifying drug-biomarker pairs from single labeling texts and 82% from mixed texts, with over 85% consistency in aligning extracted PGx categories from FDA PGx Biomarker table and relevant scientific abstracts, demonstrating its effectiveness for PGx data extraction. By integrating data from diverse sources, including scientific abstracts, this approach can support pharmacologists, regulatory bodies, and healthcare researchers in updating PGx resources more efficiently, making critical information more accessible for applications in personalized medicine. In addition, this approach shows potential of discovering novel PGx information, particularly of underrepresented minority ethnic groups. This study highlights the ability of LLMs to enhance the efficiency and completeness of PGx research, thus laying a foundation for advancements in personalized medicine by ensuring that drug therapies are tailored to the genetic profiles of diverse populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharmacogeneticsHumansDrug LabelingUnited StatesPrecision MedicineUnited States Food and Drug Administration

Stichwörter der Autor:innen

LLMsbiomarkerlarge language modelsminority ethnic groupspharmacogenomics

Autor:innen und Institutionen

  • Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, United States.
  • School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Master/Doctoral Degree Program in Toxicology, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Department of Pharmacy, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, MD, United States.
  • Immediate Office, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States.

Zitieren

APA

Li, D., Wu, L., Lin, Y. C., Huang, H. Y., Cotton, E., Liu, Q., Chen, R., Huang, R., Zhang, Y., & Xu, J. (2024). Enhancing pharmacogenomic data accessibility and drug safety with large language models: a case study with Llama3.1. Experimental Biology and Medicine. https://doi.org/10.3389/ebm.2024.10393

Vancouver

Li D, Wu L, Lin YC, Huang HY, Cotton E, Liu Q, et al. Enhancing pharmacogenomic data accessibility and drug safety with large language models: a case study with Llama3.1. Experimental Biology and Medicine. 2024. doi:10.3389/ebm.2024.10393

BibTeX
@article{Li2024,
  author = {Li, Dan and Wu, Leihong and Lin, Ying-Chi and Huang, Ho-Yin and Cotton, Ebony and Liu, Qi and Chen, Ru and Huang, Ruihao and Zhang, Yifan and Xu, Joshua},
  title = {Enhancing pharmacogenomic data accessibility and drug safety with large language models: a case study with Llama3.1},
  journal = {Experimental Biology and Medicine},
  year = {2024},
  doi = {10.3389/ebm.2024.10393}
}
Kostenlos starten →